GO:2001234 negative regulation of apoptotic signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2001234 describes any process that stops, prevents or reduces the frequency, rate or extent of apoptotic signaling pathway.
• It is a biological_process term that acts as a brake on programmed cell death, balancing survival and death signals in normal development and disease.
• Key negative regulators include itaconate, CTSG, MCPIP1, Ikaros, and MAPK feedback phosphatases that dampen pro-apoptotic kinase cascades.
• Dysregulation of this term contributes to cancer progression, autoimmune disease, and therapy resistance by allowing damaged cells to survive.
• Experimental models such as CRISPR knockout, point mutation, and overexpression cell lines are essential to dissect these pathways.
• Studying GO:2001234 helps identify therapeutic targets that restore apoptosis in cancer or prevent excessive cell death in degenerative conditions.
Description
Apoptosis is a genetically programmed form of cell death essential for tissue homeostasis, immune defense, and removal of damaged cells. The apoptotic signaling pathway is triggered by intrinsic stressors or extrinsic death ligands, leading to caspase activation and cellular dismantling. However, cells also possess robust mechanisms to inhibit or delay this pathway, collectively annotated as negative regulation of apoptotic signaling pathway (GO:2001234). This term captures any process that stops, prevents or reduces the frequency, rate or extent of apoptotic signaling pathway, ensuring that cell death occurs only when appropriate. Understanding GO:2001234 is critical because its dysregulation underlies cancer, autoimmunity, and neurodegeneration. For researchers, this term provides a framework to study how survival kinases, ubiquitin modifiers, and transcriptional regulators converge to set the threshold for apoptosis.
negative regulation of apoptotic signaling pathway At A Glance
| GO ID | GO:2001234 |
|---|---|
| GO term | negative regulation of apoptotic signaling pathway |
| Ontology | biological_process |
| Synonym | negative regulation of apoptotic signalling pathway |
| Major function | Suppression of apoptotic signaling to promote cell survival |
| Definition | Any process that stops, prevents or reduces the frequency, rate or extent of apoptotic signaling pathway. |
| Related processes | Regulation of programmed cell death, survival signaling, stress responses |
| Disease relevance | Cancer, autoimmune disorders, neurodegeneration, therapy resistance |
What Is GO:2001234?
GO:2001234, negative regulation of apoptotic signaling pathway, is defined as any process that stops, prevents or reduces the frequency, rate or extent of apoptotic signaling pathway. In practice, this includes molecular events that inhibit pro-apoptotic signaling cascades, such as blockade of death receptor activation, inhibition of mitochondrial outer membrane permeabilization, or suppression of caspase activation. It is a biological_process term that encompasses both direct physical inhibition of apoptotic machinery and indirect modulation through survival pathways.
Why Is negative regulation of apoptotic signaling pathway Important in Cell Biology?
GO:2001234 is important because it defines the molecular brakes that prevent inappropriate or excessive apoptosis. In cancer, tumor cells often hijack these negative regulators to evade cell death, leading to chemoresistance and metastasis. In autoimmune diseases, defective negative regulation can permit excessive apoptosis of healthy tissues, while in neurodegenerative conditions, enhanced negative regulation may allow damaged neurons to survive but become dysfunctional. Thus, understanding this term is essential for developing therapies that either restore apoptosis in cancer or protect cells in degenerative diseases.
• Cancer progression: negative regulators such as CTSG and MCPIP1 suppress apoptosis, promoting tumor survival.
• Therapy resistance: upregulation of anti-apoptotic signaling reduces efficacy of chemotherapy and targeted agents.
• Autoimmunity: impaired negative regulation can lead to excessive apoptosis and autoantigen release.
• Neurodegeneration: enhanced negative regulation may allow damaged neurons to escape apoptosis but contribute to dysfunction.
• Infectious disease: pathogens modulate apoptotic signaling to evade immune clearance.
• Development: precise negative regulation ensures proper tissue sculpting and immune cell selection.
• Drug discovery: targeting negative regulators can sensitize tumors to apoptosis-inducing agents.
• Biomarker development: expression of negative regulators predicts patient outcomes.
• CRISPR screening: identifying novel negative regulators of apoptosis is a major application.
• Systems biology: integrating signaling networks to model cell fate decisions.
What Happens During negative regulation of apoptotic signaling pathway?
Inhibition of Death Receptor Signaling
In simple terms: Cells can block the 'death receptors' on their surface to avoid receiving suicide signals.
Negative regulation of apoptotic signaling pathway often begins at the cell surface, where death receptors such as TRAIL receptors are inhibited. For example, MCPIP1 suppresses NF-kB signaling by negatively regulating K63-linked ubiquitylation of TRAF6, which can indirectly reduce pro-apoptotic signaling. Similarly, CTSG suppresses colorectal cancer progression through negative regulation of Akt/mTOR/Bcl2 signaling, which intersects with death receptor pathways. These mechanisms prevent the initiation of caspase-8 activation and downstream apoptosis.
Modulation of Mitochondrial Outer Membrane Permeabilization
In simple terms: The mitochondria can be prevented from leaking cell-death factors.
Mitochondrial outer membrane permeabilization (MOMP) is a point of no return in apoptosis. Negative regulators such as Bcl-2 family proteins inhibit MOMP. In colorectal cancer, CTSG negatively regulates Akt/mTOR/Bcl2 signaling, leading to reduced Bcl-2 expression and increased apoptosis. Conversely, itaconate negatively regulates the pro-apoptotic AMPK/JNK pathway in fulminant liver injury, protecting hepatocytes from apoptosis. These examples show that negative regulation can occur at the mitochondrial level by modulating kinase cascades that control Bcl-2 family proteins.
Suppression of Caspase Activation
In simple terms: The executioner enzymes of cell death can be kept in check.
Caspases are the executioners of apoptosis. Negative regulation can occur through inhibitor of apoptosis proteins (IAPs) or by blocking caspase activation platforms. For instance, Ikaros sets the threshold for negative B-cell selection by regulating the signaling strength of the AKT pathway, which influences caspase activation. MAPK-negative feedback regulation can also confer dependence to JAK2(V617F) signaling, indirectly affecting caspase activity. These mechanisms ensure that caspases are not inadvertently activated.
Regulation by Survival Kinases
In simple terms: Survival kinases act as a brake on the cell death machinery.
Survival kinases such as AKT, JNK, and AMPK are central to negative regulation of apoptotic signaling. Itaconate negatively regulates the pro-apoptotic AMPK/JNK pathway in mice with fulminant liver injury, reducing apoptosis. In colorectal cancer, CTSG suppresses progression through negative regulation of Akt/mTOR/Bcl2 signaling. MAPK-negative feedback regulation confers dependence to JAK2(V617F) signaling, highlighting how kinase feedback loops control apoptotic thresholds. These pathways are frequently dysregulated in cancer and inflammatory diseases.
Transcriptional and Post-translational Control
In simple terms: Cells can change gene expression or modify proteins to stop apoptosis.
Negative regulation of apoptotic signaling also occurs at transcriptional and post-translational levels. MCPIP1 suppresses NF-kB signaling through negative regulation of K63-linked ubiquitylation of TRAF6, altering gene expression programs that favor survival. Ikaros regulates the signaling strength of the AKT pathway, affecting B-cell selection. DCA can improve ACI-induced neurological impairment through negative regulation of Nrf2 signaling, demonstrating cross-talk with oxidative stress pathways. Valproic acid-induced EMT is regulated by AKT/GSK3beta/beta-catenin signaling, which intersects with apoptotic regulation. These layers of control ensure robust modulation of apoptosis.
Key Genes Involved in GO:2001234 negative regulation of apoptotic signaling pathway
The following genes and proteins are key players in negative regulation of apoptotic signaling pathway, as supported by the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CTSG | Suppresses colorectal cancer progression through negative regulation of Akt/mTOR/Bcl2 signaling | Potential tumor suppressor; target for apoptosis sensitization |
| MCPIP1 | Suppresses NF-kB signaling via negative regulation of K63-linked ubiquitylation of TRAF6 | Modulates inflammation and apoptosis in colorectal cancer |
| Ikaros | Sets threshold for negative B-cell selection by regulating AKT pathway signaling strength | Critical for B-cell development and leukemia |
| TRAF6 | K63-linked ubiquitylation target; its negative regulation by MCPIP1 reduces NF-kB survival signaling | Central node in inflammatory and apoptotic pathways |
| AKT | Survival kinase; negatively regulated by CTSG and modulated by Ikaros | Frequent target in cancer therapy |
| mTOR | Kinase in survival signaling; negatively regulated by CTSG | Target of rapamycin analogs in cancer |
| Bcl2 | Anti-apoptotic protein; negatively regulated by CTSG via Akt/mTOR | Predictive biomarker and therapeutic target |
| AMPK | Pro-apoptotic kinase; negatively regulated by itaconate | Metabolic stress sensor in liver injury |
| JNK | Pro-apoptotic kinase; negatively regulated by itaconate | Stress-activated kinase in apoptosis |
| Nrf2 | Transcription factor; negatively regulated by DCA in neurological impairment | Oxidative stress response |
| GSK3beta | Kinase in AKT/GSK3beta/beta-catenin pathway; regulated by valproic acid | EMT and apoptosis crosstalk |
| beta-catenin | Transcription co-activator; regulated by AKT/GSK3beta | Cell adhesion and survival |
| JAK2(V617F) | Mutant kinase; MAPK-negative feedback regulation confers dependence | Myeloproliferative neoplasms |
| TRAIL | Death ligand; its signaling is negatively regulated in cancer | Therapeutic agonist in clinical trials |
| Death receptors | Cell surface receptors; negative regulation prevents apoptosis initiation | Targets for agonist antibodies |
| NF-kB | Survival transcription factor; negatively regulated by MCPIP1 | Inflammation and cancer |
| Itaconate | Metabolite; negatively regulates pro-apoptotic AMPK/JNK pathway | Immunometabolism and liver injury |
| DCA | Compound; negatively regulates Nrf2 signaling | Neuroprotection |
How Is negative regulation of apoptotic signaling pathway Regulated?
Negative regulation of apoptotic signaling pathway is itself tightly regulated. Survival kinases such as AKT and mTOR are controlled by upstream growth factor receptors and phosphatases. MAPK-negative feedback loops can adjust signaling strength and confer dependence on mutant kinases like JAK2(V617F). Transcriptional regulators such as Ikaros set thresholds for B-cell selection by modulating AKT pathway activity. Post-translational modifications, including K63-linked ubiquitylation of TRAF6, are reversed by deubiquitinases like MCPIP1. Metabolic cues, such as itaconate, can suppress pro-apoptotic AMPK/JNK signaling. These layers of regulation ensure that apoptosis is executed only when appropriate.
negative regulation of apoptotic signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CTSG | Colorectal cancer progression | KO and overexpression in HCT116 cells |
| MCPIP1 | Colorectal cancer and inflammation | Knockout in CRC cell lines |
| Ikaros | B-cell selection and leukemia | Point mutation in B-cell lines |
| TRAF6 | NF-kB signaling in cancer | Knock-in of ubiquitylation-deficient mutant |
| JAK2(V617F) | Myeloproliferative neoplasms | Knock-in mutant in hematopoietic cells |
Cancer
In cancer, negative regulation of apoptotic signaling pathway is often enhanced, allowing tumor cells to evade cell death. CTSG suppresses colorectal cancer progression through negative regulation of Akt/mTOR/Bcl2 signaling, and its loss may promote apoptosis resistance. MCPIP1 suppresses NF-kB signaling by negatively regulating K63-linked ubiquitylation of TRAF6, impacting colorectal cancer. TRAIL/death receptor signaling is frequently dysregulated in cancer, contributing to metastasis. Targeting these negative regulators can sensitize tumors to apoptosis-inducing therapies.
Autoimmune and Inflammatory Diseases
Dysregulated negative regulation of apoptosis can lead to autoimmune diseases. Ikaros sets the threshold for negative B-cell selection by regulating AKT pathway signaling strength; defects can result in autoantibody production. MCPIP1-mediated negative regulation of NF-kB signaling is critical for controlling inflammation. Itaconate negatively regulates pro-apoptotic AMPK/JNK pathway in fulminant liver injury, protecting against excessive apoptosis. These pathways are potential therapeutic targets for autoimmune and inflammatory conditions.
Neurological Disorders
In neurological impairment, negative regulation of apoptotic signaling can be protective or detrimental. DCA improves ACI-induced neurological impairment through negative regulation of Nrf2 signaling pathway, suggesting that modulating apoptosis regulators can affect recovery. Valproic acid-induced EMT is regulated by AKT/GSK3beta/beta-catenin signaling, which intersects with apoptotic pathways in triple negative breast cancer, but similar mechanisms may operate in neural cells. Understanding these pathways is crucial for developing neuroprotective strategies.
From negative regulation of apoptotic signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of CTSG increase apoptosis resistance? | CTSG knockout colorectal cancer cell line |
| Does MCPIP1 deubiquitylate TRAF6 to suppress NF-kB? | MCPIP1 knockout with TRAF6 ubiquitylation assays |
| How does Ikaros threshold affect B-cell selection? | Ikaros point mutant knock-in in B-cell lines |
| Does itaconate protect hepatocytes via AMPK/JNK? | Itaconate treatment in AMPK/JNK knockout mice |
| Can MAPK feedback inhibition target JAK2(V617F)? | JAK2(V617F) knock-in with MAPK inhibitors |
| Does DCA modulate Nrf2 to improve neurological outcome? | Nrf2 knockout in ACI models |
How to Study the negative regulation of apoptotic signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Gene essentiality for apoptosis resistance | Identify novel negative regulators |
| RNA-seq | Transcriptional changes | Measure NF-kB target genes upon MCPIP1 loss |
| Phosphoproteomics | Kinase signaling activity | Assess AKT/mTOR pathway modulation |
| Annexin V/PI flow cytometry | Apoptotic cell percentage | Validate apoptosis induction |
| Caspase-3/7 activity assay | Caspase activation | Quantify apoptosis execution |
| TUNEL staining | DNA fragmentation | Detect apoptosis in tissues |
| Live-cell imaging | Mitochondrial membrane potential | Monitor MOMP dynamics |
| Ubiquitylation assays | K63-linked ubiquitin chains | Study TRAF6 regulation by MCPIP1 |
CRISPR Knockout Screening
Genome-wide CRISPR knockout screens can identify novel negative regulators of apoptotic signaling pathway. By treating cells with apoptosis inducers and sequencing sgRNAs, researchers can find genes whose loss sensitizes or desensitizes cells to apoptosis. This approach has been used to uncover pathways involving AKT and MAPK feedback.
Transcriptomics and Proteomics
RNA-seq and proteomics can reveal changes in gene expression and protein abundance upon modulation of negative regulators. For example, MCPIP1 knockout alters NF-kB target genes. Phosphoproteomics can identify signaling changes in AKT/mTOR pathways.
Apoptosis Assays
Flow cytometry with Annexin V/PI staining, caspase activity assays, and TUNEL staining are standard to measure apoptosis rates. These assays are used to validate findings from CRISPR screens and drug treatments.
Imaging and Reporter Systems
Live-cell imaging with fluorescent reporters for mitochondrial membrane potential or caspase activation can visualize apoptotic dynamics. These methods help study real-time effects of negative regulators.
How CRISPR Can Be Used to Study GO:2001234 negative regulation of apoptotic signaling pathway
Knockout
CRISPR knockout of negative regulators such as CTSG or MCPIP1 can reveal their role in apoptosis. For example, CTSG knockout in colorectal cancer cells may increase apoptosis sensitivity. MCPIP1 knockout can enhance NF-kB signaling and alter apoptosis. These models are essential for target validation.
Point Mutation
Point mutations can mimic disease-associated variants or disrupt specific phosphorylation sites. For instance, point mutations in Ikaros can alter its threshold-setting function in B-cell selection. JAK2(V617F) is a point mutant that confers dependence on MAPK feedback. CRISPR point mutation models help dissect precise molecular mechanisms.
Knock-in
Knock-in of tagged or mutant proteins allows tracking and functional studies. For example, knocking in a ubiquitylation-deficient TRAF6 mutant can test the role of K63-linked ubiquitylation in NF-kB signaling. Knock-in of fluorescent reporters can visualize apoptotic dynamics.
Overexpression
Overexpression of negative regulators such as CTSG or MCPIP1 can suppress apoptosis and promote survival. These models are useful to study gain-of-function effects and test therapeutic resistance. Overexpression of Bcl2 or other anti-apoptotic proteins is common in cancer models.
How EDITGENE Supports negative regulation of apoptotic signaling pathway Research
Researchers studying negative regulation of apoptotic signaling pathway-related genes often need to determine whether a candidate gene is causally involved in suppressing apoptosis, and which domains or residues mediate this function. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models that answer these questions.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of apoptotic signaling pathway research.
Frequently Asked Questions About negative regulation of apoptotic signaling pathway
What is GO:2001234?
GO:2001234 is the Gene Ontology term for negative regulation of apoptotic signaling pathway, defined as any process that stops, prevents or reduces the frequency, rate or extent of apoptotic signaling pathway.
What genes are involved in negative regulation of apoptotic signaling pathway?
Key genes include CTSG, MCPIP1, Ikaros, TRAF6, AKT, mTOR, Bcl2, AMPK, JNK, and JAK2, among others.
How does negative regulation of apoptosis contribute to cancer?
Cancer cells often enhance negative regulation to evade apoptosis, leading to therapy resistance and metastasis.
What is the difference between pro-apoptotic and anti-apoptotic signaling?
Pro-apoptotic signaling promotes cell death, while anti-apoptotic (negative regulation) signaling suppresses it, maintaining a balance.
Which diseases are associated with dysregulated negative regulation of apoptosis?
Cancer, autoimmune diseases, inflammatory conditions, and neurological disorders are associated with dysregulation.
How can CRISPR be used to study negative regulation of apoptotic signaling?
CRISPR knockout, point mutation, knock-in, and overexpression models allow functional dissection of genes in this pathway.
What are the main signaling pathways in negative regulation of apoptosis?
AKT/mTOR, NF-kB, MAPK, AMPK/JNK, and Nrf2 pathways are key.
What experimental methods are used to measure apoptotic signaling?
Flow cytometry, caspase assays, TUNEL, RNA-seq, proteomics, and imaging are commonly used.
What is the role of MCPIP1 in apoptosis?
MCPIP1 suppresses NF-kB signaling by negatively regulating K63-linked ubiquitylation of TRAF6, affecting apoptosis in colorectal cancer.
How does itaconate regulate apoptosis?
Itaconate negatively regulates the pro-apoptotic AMPK/JNK pathway in fulminant liver injury, protecting cells from apoptosis.
Conclusion
GO:2001234, negative regulation of apoptotic signaling pathway, is a fundamental biological process that controls cell survival and death decisions. Its dysregulation is implicated in cancer, autoimmunity, and neurological disorders, making it a rich area for therapeutic targeting. Advances in CRISPR technology and functional genomics enable precise dissection of these pathways, from individual genes to genome-wide screens. Continued research will uncover new negative regulators and translate them into clinical applications.
References
- 1. Fan K et al.. 2023. Negative regulation of pro-apoptotic AMPK/JNK pathway by itaconate in mice with fulminant liver injury.. Cell Death Dis 14(7):486 PMID: 37524706
- 2. Chan S et al.. 2023. CTSG Suppresses Colorectal Cancer Progression through Negative Regulation of Akt/mTOR/Bcl2 Signaling Pathway.. Int J Biol Sci 19(7):2220-2233 PMID: 37151875
- 3. Ye W et al.. 2023. MCPIP1 Suppresses the NF-κB Signaling Pathway Through Negative Regulation of K63-Linked Ubiquitylation of TRAF6 in Colorectal Cancer.. Cancer Gene Ther 30(1):96-107 PMID: 36076064
- 4. Ehm PAH et al.. 2024. Ikaros sets the threshold for negative B-cell selection by regulation of the signaling strength of the AKT pathway.. Cell Commun Signal 22(1):360 PMID: 38992657
- 5. Oh YT et al.. 2021. Regulation of Cancer Metastasis by TRAIL/Death Receptor Signaling.. Biomolecules 11(4) PMID: 33810241
- 6. Kesarwani M et al.. 2023. MAPK-negative feedback regulation confers dependence to JAK2(V617F) signaling.. Leukemia 37(8):1686-1697 PMID: 37430058
- 7. Bian KY et al.. 2019. DCA can improve the ACI-induced neurological impairment through negative regulation of Nrf2 signaling pathway.. Eur Rev Med Pharmacol Sci 23(1):343-351 PMID: 30657576
- 8. Ozman Z et al.. 2021. Regulation of valproic acid induced EMT by AKT/GSK3β/β-catenin signaling pathway in triple negative breast cancer.. Mol Biol Rep 48(2):1335-1343 PMID: 33515347
